Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16233046 | 0.90 | ALDH1A1 (0.44) | POLBALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL24838382 | 0.86 | OPRL1 (0.42) | KDM4EPOLB | |
| SCHEMBL25605767 | 0.84 | POLB (0.38) | KDM4EPOLBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL25605868 | 0.84 | POLB (0.38) | KDM4EPOLBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL24838153 | 0.81 | KDM4E (0.51) | KDM4EPOLBALDH1A1ALOX15HTT | |
| SCHEMBL21026134 | 0.80 | CHRM5 (0.53) | KDM4EPOLBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL25605855 | 0.80 | HTR7 (0.45) | KDM4EPOLBHTTMEN1KMT2A | |
| SCHEMBL29341386 | 0.79 | KDM4E (0.53) | KDM4EPOLBALDH1A1ALOX15HTT | |
| SCHEMBL20234289 | 0.77 | POLB (0.48) | KDM4EPOLBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL13005085 | 0.77 | KDM4E (0.46) | KDM4EPOLBALDH1A1ALOX15RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | KDM4E 223/4885POLB 22/4885ALDH1A1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.